The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis

Yuval Volfovitch1,2 · Avishai M. Tsur1,3,4 · Michael Gurevitch1 · Daniela Novick5 · Roy Rabinowitz6 · Mathilda Mandel1 · Anat Achiron1 · Menachem Rubinstein5 · Yehuda Shoenfeld1,7,8,9 · Howard Amital1

Received: 6 March 2022 / Accepted: 15 August 2022 / Published online: 12 October 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract
Coronavirus disease 2019 (COVID-19) is associated with immune dysregulation, severe respiratory failure, and multiple organ dysfunction caused by a cytokine storm involving high blood levels of ferritin and IL-18. Furthermore, there is a resemblance between COVID-19 and macrophage activation syndrome (MAS) characterized by high concentrations of soluble CD163 (sCD163) receptor and IL-18. High levels of ferritin, IL-18, and sCD163 receptor are associated with “hyperferritinemic syndrome”, a family of diseases that appears to include COVID-19. In this retrospective cohort study, we tested the association and intercorrelations in the serum levels of ferritin, sCD163, and IL-18 and their impact on the prognosis of COVID-19. We analyzed data of 70 hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The levels of sCD163, ferritin, and IL-18 were measured and the correlation of these parameters with the respiratory deterioration and overall 30-day survival was assessed. Among the 70 patients, 60 survived 30 days from hospitalization. There were substantial differences between the subjects who were alive following 30 days compared to those who expired. The differences were referring to lymphocyte and leukocyte count, CRP, D-dimer, ferritin, sCD163, and IL-18. Results showed high levels of IL-18 (median, 444 pg/mL in the survival group compared with 916 pg/mL in the mortality group, \( p \)-value \( 8.54 \times 10^{-2} \)), a statistically significant rise in levels of ferritin (median, 484 ng/mL in the survival group compared with 1004 ng/mL in the mortality group \( p \)-value, \( 7.94 \times 10^{-3} \)), and an elevated value of in sCD163 (mean, 559 ng/mL in the survival group compared with 840 ng/mL in the mortality group, \( p \)-value 1.68 \( \times \) 10\(^{-2} \)). There was no significant correlation between the rise of ferritin and the levels sCD163 or IL-18. Taken together, sCD163, ferritin, and IL-18 were found to correlate with the severity of COVID-19 infection. Although these markers are associated with COVID-19 and might contribute to the cytokine storm, no intercorrelation was found among them. It cannot be excluded though that the results depend on the timing of sampling, assuming that they play distinct roles in different stages of the disease course. The data represented herein may provide clinical benefit in improving our understanding of the pathological course of the disease. Furthermore, measuring these biomarkers during the disease progression may help target them at the right time and refine the decision-making regarding the requirement for hospitalization.

Keywords Hyperferritinemic syndrome · Ferritin · Cytokine storm · sCD163 · IL-18 · Macrophage activation syndrome · COVID-19 · SARS-CoV-2

Introduction
Coronavirus disease 2019 (COVID-19) is caused by the virus known as SARS-CoV-2 and has been declared a worldwide pandemic by the World Health Organization in February 2020. Until now, the infection was confirmed in more than 617 million cases, with a mortality record of over 6.53 million deaths [1, 2]. Hence, there is an ongoing need for better understanding and identifying its pathogenesis in parallel to the attempts in developing novel therapeutics. SARS-CoV-2 infects the respiratory tract resulting in pneumonia and acute respiratory distress syndrome (ARDS) in about 15% of the cases [3]. Patients with a severe course often show high concentrations of ferritin in their blood which correlate with the severity of their disease [3, 4]. Furthermore, a growing body of clinical data suggests that...
the severity, prognosis, and mortality in COVID-19 patients may be linked to the presence of the so-called “cytokine storm” induced by the virus [5–10]. Cytokine storm is an umbrella term encompassing several disorders of immune dysregulation and was recently redefined on the basis of the following criteria: elevated circulating cytokine levels, acute systemic inflammatory symptoms, and secondary organ dysfunction beyond that which could be attributed to a normal response to a pathogen, if a pathogen is present [7]. Patients, who had been shown to have laboratory findings compatible with a cytokine storm, also experienced deleterious clinical manifestations and higher mortality rates [6]. Furthermore, COVID-19 patients, who required mechanical ventilation, developed consequent lung injury that is also associated with the release of the inflammatory factors, apoptosis, endothelial dysfunction, and activation of the coagulation system [11]. CT tests of COVID-19 lung involvement showed a certain degree of similarity to findings seen in MAS. Both diseases manifested similarity in ground-glass opacities (GGOs) extension and pattern of parenchymal consolidation, except for apical consolidations which were more frequent in COVID-19 than MAS [12].

Interestingly, the cytokine storm observed in COVID-19 patients is similar to that presented in other hyperferritinemic conditions [13]. In addition to ferritin, additional cytokines classically seen in hyperferritinemic syndrome are also associated with COVID-19, e.g., IL-6 and IL-18 [9, 10, 14–16]. Among the markers classically seen in hyperferritinemic syndrome, we focused on two main candidates that possibly may link to the hyperferritinemic syndrome and COVID-19, IL-18 and sCD163 receptor, and we investigated their correlation with the severity of the disease.

IL-18 was first identified as interferon gamma inducing factor that enhances inflammation [17]. It belongs to the IL-1 family [18] and had been associated with various cytokine disorders [7]. This cytokine has effector and regulatory roles in a variety of early inflammatory responses. IL-18 level in the blood is strongly associated with septicemia and ARDS risk and often predicts mortality [19]. Furthermore, recent studies show that IL-18 rises not only in hyperferritinemic hyperinflammatory conditions such as macrophage activating syndrome (MAS), septicemia, and ARDS but also in COVID-19 along with IL-6 [9, 10, 20].

CD163 is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and is exclusively expressed in monocytes and macrophages. It functions as an acute phase-regulated receptor involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages [16]. CD163 is commonly denoted as soluble-CD163 (sCD163), which is generated by ectodomain shedding of the membrane bound receptor, as a result of enzymatic cleavage by ADAM17/TACE metalloproteinase [21, 22]. sCD163 is released into the sera during macrophage activation, therefore considered a marker of macrophage activation [16]. Over-expression of sCD163 has been observed in several inflammatory diseases such as MAS and the adult-onset Still’s disease [16]. Over the course of MAS, the sCD163 was already positively correlated with ferritin serum levels, suggesting a possible pathogenic relationship between these molecules [16].

Table 1. Clinical evaluations, complete blood count, coagulation factors, and liver and kidney function factors of the patients taken from admission. Values are depicted for two groups — patients who survived 30 days from hospitalization (survival group) and patients who did not (mortality group).

| Characteristic | 30-day mortality, N=10 [1] | 30-day survival, N=60 [1] | p-Value [2] |
|---------------|-----------------------------|---------------------------|------------|
| Temperature (°C) | 37.2 (36.8, 37.6) | 37.2 (36.8, 37.7) | 0.906 |
| Systolic pressure (mmHg) | 117 (106, 122) | 124 (111, 139) | 0.102 |
| Diastolic pressure (mmHg) | 73 (66, 79) | 73 (67, 80) | 0.65 |
| Respiratory rate (B/m) | 24 (16, 30) | 18 (16, 22) | 0.419 |
| Saturation (%) | 93 (92, 95) | 95 (92, 97) | 0.445 |
| RBC (cells/mcL) | 5 (4, 5) | 5 (4, 5) | 0.311 |
| PLT (K/mL) | 244 (183, 300) | 186 (132, 251) | 0.156 |
| WBC (K/µL) | 9.9 (8.1, 13.3) | 6.8 (5.1, 9.6) | 0.0285 |
| Lymphocytes (K/µL) | 57 (34, 75) | 140 (84, 210) | 0.00451 |
| CRP (mg/L) | 215 (134, 292) | 87 (46, 136) | 0.00081 |
| Ferritin (ng/mL) | 767 (590, 1,058) | 418 (225, 805) | 0.0834 |
| D-dimer (ng/mL) | 1,333 (827, 4,752) | 613 (504, 1,041) | 0.0208 |
| INR | 1.2 (1.1, 1.2) | 1.1 (1.0, 1.2) | 0.198 |
| ALT (IU/I) | 26 (18, 56) | 28 (21, 42) | 0.945 |
| Creatinin (mg/dL) | 1.2 (0.9, 1.4) | 0.8 (0.7, 1.1) | 0.0155 |

[1] Statistics presented: median (IQR) [2]. Statistical tests performed: Wilcoxon rank-sum test. Clinical and laboratory values of the 70 COVID-19 patients elicited from blood samples taken at admission. Higher levels of WBC, CRP, D-dimer, and creatinine were significantly associated with 30-day mortality. Lower levels of lymphocytes were significantly associated with 30-day mortality.
We hypothesize that COVID-19 has a common pathophysiological mechanism with the hyperferritinemic syndrome in general; therefore, we tested the levels of these three markers — ferritin, IL-18, and sCD163, and calculated the correlations among them.

### Methods

This research is a retrospective cohort study based on 70 hospitalized patients verified for COVID-19 by Sheba Medical Center. The research has an IRB approval (number 7132–20-SMC) granted from the Sheba Medical Center. All 70 patients admissions had taken place between 8th of March and the 28th of April 2020.

Clinical evaluations and laboratory values of blood samples throughout their hospitalization were taken from the hospital records. The clinical assessment included fever, blood pressure, necessity of invasive ventilation, saturation, and need of ventilation support. Laboratory values included levels of ferritin, RBCs, leukocytes, lymphocytes, platelets, CRP, D-dimer, INR, ALT, creatinine, TSH, IL-1β, IL-6, IL-8, and TNFα. IL-18 plasma levels were measured with the DL180 Human Total IL-18/IL-1F4 Quantikine ELISA Kit according to the manufacturer instructions.

### Table 2

| Characteristic          | 30-day mortality, N=10 [1] | 30-day survival, N=60 [1] | p-Value [2] |
|-------------------------|-----------------------------|---------------------------|-------------|
| Temperature (°C)        | 37.9 (37.7, 38.5)           | 38.0 (37.5, 38.9)         | 0.86        |
| Systolic pressure (mmHg)| 122 (82, 161)               | 136 (98, 156)             | 0.551       |
| Diastolic pressure (mmHg)| 67 (48, 78)                | 71 (60, 81)               | 0.302       |
| Respiratory rate (B/m)  | 34 (26, 36)                 | 25 (23, 30)               | 0.0675      |
| Saturation (%)          | 78 (70, 84)                 | 89 (84, 93)               | 0.0135      |
| RBC (cells/mL)          | 3 (3, 3)                    | 4 (3, 5)                  | 0.298       |
| PLT (K/mL)              | 131 (71, 409)               | 173 (108, 456)            | 0.86        |
| WBC (K/µL)              | 25.4 (13.7, 33.9)           | 12.3 (7.2, 16.3)          | 0.00591     |
| Lymphocytes (K/µL)      | 16 (14, 22)                 | 75 (36, 134)              | 0.000188    |
| CRP (mg/L)              | 315 (192, 352)              | 186 (109, 303)            | 0.0358      |
| Ferritin (ng/mL)        | 1,560 (1,071, 4,521)        | 860 (395, 1,512)          | 0.00719     |
| D-dimer (ng/mL)         | 6,991 (4,396, 54,524)       | 2,076 (679, 8,285)        | 0.0192      |
| INR                     | 1.3 (1.2, 1.3)              | 1.2 (1.2, 1.4)            | 0.395       |
| ALT (IU/L)              | 78 (48, 165)                | 64 (39, 105)              | 0.421       |
| Creatinin (mg/dL)       | 4.0 (1.8, 4.7)              | 1.0 (0.7, 1.3)            | 0.000106    |

[1] Statistic presented: median (IQR); n(%). [2] Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence.

### Table 3

| Characteristic         | 30-day mortality, N=10 [1] | 30-day survival, N=60 [1] | p-Value [2] |
|------------------------|-----------------------------|---------------------------|-------------|
| Ferritin (ng/mL)       | 1,004 (851, 1,405)          | 484 (235, 1,023)          | 0.00794     |
| IL-18 (pg/mL)          | 916 (431, 1,104)            | 444 (297, 714)            | 0.0854      |
| sCD163 (ng/mL)         | 840 (673, 1,227)            | 559 (388, 739)            | 0.0168      |

[1] Statistic presented: median (IQR); n(%). [2] Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence.

The levels of sCD163 and IL-18 were measured from blood tests a few days following admission (5.1 days on average), by next-generation enzyme-linked immunosorbent assay (ELISA) (Simple PlexTM Ella microfluidic platform, Protein Simple, CA, USA). Briefly, 25 μL diluted serum samples was added to a microfluidic cartridge, automatically separated into triplicates, and coated with sCD163 or IL-18 specific capture monoclonal antibodies. Detection of the antibodies and streptavidin-DyLight650 conjugates, as well as all washing steps,
was automatically performed. Raw data were analyzed using the SimplePlex Explorer software. All values other than sCD163 and IL-18 were taken twice — from time of admission of peak levels throughout hospitalization. In addition, a third value of ferritin was taken from the same day in which blood samples were taken to assess the levels of sCD163 and IL-18.

Population study  The study cohort included 70 hospitalized patients which were randomly selected in the internal medicine division converted to COVID-19 department in Sheba
Medical Center. Inclusion criteria were positive RT-PCR test for SARS-CoV-2 and the need for hospitalization (as both are admission criteria into Sheba COVID-19 division). Among those patients, there were no exclusion criteria.

The cohort of 70 patients was classified into two groups, those who survived 30 days from hospitalization (60 patients) and those who did not (10 patients). Follow-up time was during 2 months from hospitalization.

In the further part of the study, we categorized the cohort study population into two groups: “severe group” as patients who needed invasive ventilation support during hospitalization and “mild group” which included the rest of the patients.

Categorical variables were presented as n (%) and compared using chi-square test of independence; continuous variables were presented as median (IQR) and compared using Wilcoxon rank-sum test. Correlations were assessed using the Spearman’s method. Logistic regression models were used to assess the odds ratio between predictors and the outcome. p-Value < 0.05 was considered statistically significant.

Results

The two groups of patients were evaluated twice for their clinical parameters, once at admission (Table 1) and once during the hospitalization (Table 2). In addition, levels of IL-18 and sCD163 were measured short after admission (with average of 5.14 days after) (Table 3). Ferritin levels were measured 3 times, at admission (Table 1), peak levels during hospitalization (Table 2), and short after admission.
along with IL-18 and sCD163 for intercorrelation analysis purposes (Table 3).

At first, we measured and compared laboratory values which are commonly taken in practice (Fig. 1). While comparing values taken at admission, there was a substantial difference in the lymphocytes count (median, 59 K/µL in the mortality group compared with 140 K/µL in the survival group), which is typical to viral infections and
particularly in COVID-19 (Table 1). In addition, there were differences in the CRP (median, 215 mg/L in the mortality group compared with 87 mg/L in the survival group), leukocytes (median, 9.9 K/µL in the mortality group compared with 6.8 K/µL in the survival group), and D-dimer (median, 1333 ng/mL in the mortality group compared with 613 ng/mL in the survival group) which were all higher in the mortality group (Table 1). Notably, all the patients who admitted with CRP levels lower than 90 mg/L and D-dimer level lower than 600 ng/mL survived (Fig. 2, depicted in violin plots [23]). Additionally, we examined the correlation between distinct markers found to be associated with the prognosis of COVID-19 (Figs. 3, 4, 5, and 6): high CRP and low lymphocytes appear to be risk markers for 30 days mortality.

Besides values taken at admission, we collected clinical and laboratory peak level records throughout hospitalization and compared the records of the mortality group with the survival group (Table 2). Similarly to values at admission (Table 1), lower lymphocytes count (median, 16 K/µL in the mortality group compared with 75 K/µL in the survival group), and higher levels of WBC (median, 25.4 K/µL in the mortality group compared with 12.3 K/µL in the survival group), CRP (median, 315 mg/L in the mortality group compared with 186 mg/L in the survival group) and creatinine (median, 4 mg/dL in the mortality group compared with 1 mg/dL in the survival group), were significantly associated with 30-day mortality. Furthermore, all patients with lymphocytes count higher than 40 K/µL throughout hospitalization survived (Fig. 3). Another considerable finding is that patients who reached higher levels of ferritin had worse survival outcome (Fig. 3). High ferritin levels showed a statistical significance in the mortality group with a median of 1569 ng/mL compared with 860 ng/mL in the survival group, which strengthens the association between COVID-19 and hyperferritinemic syndrome (Table 2). In the analysis of ferritin levels with peak lymphocytes count, 3 out of 4 quarters survived, showing that 100% of the patients with ferritin levels lower than 500 ng/ml, and/or lymphocytes higher than 40 K/µL survived. Furthermore, 10 out of 19 patients with lowest lymphocytes value below 40 K/µL and highest ferritin above 500 ng/ml died within 30 days (53%) (Fig. 6a).

Alongside the clinical and laboratory assessment of marker commonly taken in practice, we collected a blood sample of each patient obtained short after admission
The samples collected were tested for levels of sCD163, IL-18, and ferritin (Table 3). As expected from the previous studies, IL-18 levels were higher in the mortality group (median, 916 pg/ml compared with 444 pg/ml in the survival group), but interestingly, the differences in ferritin levels and sCD163 levels were even more significant in the mortality group (median, 1004 ng/ml compared with 484 ng/ml in the survival group, and 840 ng/ml compared with 559 ng/ml in the survival group, respectively), indicating a correlation between COVID-19, hyperferritinemic syndrome in general, and macrophage activation syndrome in particular (Table 3, Fig. 4).

In the last part of our research, we compared the usage of invasive ventilation or extracorporeal membrane oxygenation (ECMO) between the mortality and the survival groups. Expectedly, invasive ventilation and ECMO were significantly associated with 30-day mortality (Table 4). Assessing for total mortality further than 30 days mortality, 13% of the patients in the 30-day survival group died during the post 30 days 2 months of follow-up. Afterwards, we classified the patients into two other groups — patients who needed invasive ventilation or ECMO (severe group, $n = 27$) and patients who discharged without it (mild group, $n = 43$). For both groups, we assessed the aforementioned clinical and laboratory markers (Table 5). High levels of CRP, D-dimer, lymphopenia, sCD163, and IL-18 levels were associated with invasive ventilation support, with median value differences of 709 pg/ml in the severe group compared to 393 pg/ml in the mild group referring to IL-18, and 716 ng/ml in the severe group compared to 453 ng/ml in the mild group regarding sCD163 (Table 5).

**Discussion**

Our study focuses on COVID-19, hyperferritinemia, and a cytokine storm which is common to both conditions and might share a common pathophysiology. Cytokine storm appears in hyperferritinemic syndromes, such as MAS, adults onset Still’s disease (AOSD), catastrophic antiphospholipid syndrome, and septic shock [24]. These disorders are characterized by high levels of serum ferritin and high levels of inflammatory cytokines such as IL-1, IL-6, IL-8, IL-18, TNFα, and sCD163 receptor as part of the aforementioned cytokine storm [7–10, 24, 25]. Ferritin appears to be a key marker of and a pathogenic player in inflammatory
processes through signaling pathways involving innate immune response and modulation of lymphocyte function [26]. According to the previous studies, ferritin can act as a pro-inflammatory but also as an anti-inflammatory molecule. Regarding the question how ferritin signals in those two opposite pathways, the consensus is that it depends on which subunit of the molecule is activated, namely, the ferritin H subunit or L subunit [13, 24, 27]. Ferritin H subunit (FeH) has shown an iron-independent stimulatory effect on NF-κB, leading to the production of pro-inflammatory molecules [13]. On the other hand, the ferritin L subunit (FeL) has shown an opposite anti-inflammatory effect by inhibiting NF-κB [13]. Interestingly, the pro-inflammatory cytokines which are elevated in hyperferritinemic syndrome have also been described in severe COVID-19 [13] and may preferentially induce the expression of FeH via FER2, a regulatory element acting as a binding site to NF-κB. The latter, in turn, stimulates the synthesis of further FeH and pro-inflammatory cytokines, thus perpetuating a vicious inflammatory loop [13]. Accordingly, in our study, there was a strong association between ferritin and COVID-19 along the progression of the disease, with a worse outcome and higher mortality rate. Therefore, we suggest that in COVID-19 patients, there is a cytokine storm involving the same FeH inflammatory loop seen in hyperferritinemic syndrome, manifested in the disease progression and prognosis.

IL-18 is a pro-inflammatory cytokine expressed at sites of chronic inflammation, in autoimmune diseases, a variety of cancers, and in numerous infectious diseases [18, 28]. Like IL-1β, IL-18 is synthesized as an inactive precursor missing a signal peptide and the caspase-1-mediated cleavage is needed for its activation [29, 30]. The transcription of IL-18 precursor is further increased during infection after toll-like receptor (TLR) binding of PAMPs. As a result, an activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway occurs [29]. IL-18 synergizes with interleukin-12 (IL-12) or interleukin-15 (IL-15) to stimulate secretion of interferon-γ from T cells and NK cells, and thus promotes Th1-type inflammatory responses [7]. IL-18 is regulated by the naturally occurring and very potent antagonist, the IL-18 binding protein (IL-18BP) [17]. A drug which blocks IL-18 activity, named Tadekinig alfa (a recombinant IL-18BP), is currently in clinical studies targeting IL-18 in various conditions of hyperinflammation.
such as MAS associated with AOSD and MAS resulting from a mutation in the inflammasome [31, 32]. In our study, IL-18 has been shown to correlate with higher mortality rate in COVID-19 patients (Fig. 4), together with ferritin and sCD163. Therefore, rise in IL-18 levels, which is known to occur due to NF-κB activation, might be a product of the aforementioned FeH-NF-κB inflammatory loop and might be a factor in the disease progression as well. Thus, Tadeking alfa might serve as a potential therapeutic candidate also for COVID-19.

sCD163 receptor is upregulated in numerous inflammatory diseases, including MAS, RA, lupus nephritis, sepsis and also in cirrhosis, type 2 diabetes, Gaucher’s disease, HIV infection, and Hodgkin lymphoma [32–34]. Furthermore, serum sCD163 levels profoundly increase with the progress of MAS and correlate positively with the disease activity of systemic juvenile idiopathic arthritis (s-JIA), even in patients receiving immunosuppressive drugs such as tocilizumab [33]. During MAS, levels of sCD163 seem to be strongly related to the degree of macrophage activation [16].

sCD163 is also known to be related to ferritin via ferritin H subunit which was found to be an activator of macrophages and as part of this activation levels of sCD163 increase [34].

### Table 4

Usage percentage of different kinds of ventilation support throughout hospitalization. Values are depicted for two groups — patients who survived 30 days from hospitalization (survival group) and patients who did not (mortality group).

| Characteristic | 30-day mortality, N=10 [1] | 30-day survival, N=60 [1] | p-Value [2] |
|---------------|---------------------------|--------------------------|-------------|
| Ventilatory support | | | 0.0185 |
| ECMO | 1 (10%) | 3 (5.0%) | |
| Invasive | 8 (80%) | 15 (25%) | |
| Nasal cannula | 1 (10%) | 16 (27%) | |
| Non rebreather | 0 (0%) | 8 (13%) | |
| None | 0 (0%) | 17 (28%) | |
| Vapotherm | 0 (0%) | 1 (1.7%) | |
| Ventilatory support grading | | | 0.00112 |
| Severe | 9 (90%) | 18 (30%) | |
| Mild | 1 (10%) | 42 (70%) | |
| Mortality total | 10 (100%) | 8 (13%) | <0.00005 |

[1] Statistics presented: median (IQR); n(%) [2]. Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence. Comparison of invasive ventilation support usage throughout hospitalization. Invasive ventilation and ECMO were significantly associated with 30-day mortality.

### Table 5

Invasive ventilation as outcome among hospitalized patients clinical evaluations, complete blood count, coagulation factors, and liver and kidney function factors of the patients taken from admission. Values are depicted for two groups — patients who required invasive ventilation support (severe group) and patients who did not (mild group).

| Characteristic | Severe, N=27 [1] | Mild, N=43 [1] | p-Value [2] |
|---------------|------------------|---------------|-------------|
| Temperature (°C) admission | 37.2 (37.0, 37.8) | 37.1 (36.8, 37.5) | 0.411 |
| Systolic pressure (mmHg) admission | 123 (112, 136) | 123 (110, 140) | 0.612 |
| Diastolic pressure (mmHg) admission | 73 (66, 80) | 72 (69, 80) | 0.633 |
| Respiratory rate admission (B/m) | 17 (16, 22) | 20 (17, 22) | 0.365 |
| Saturation (%) admission | 94 (92, 95) | 95 (90, 97) | 0.323 |
| RBC admission (cells/mcL) | 5 (4, 5) | 5 (4, 5) | 0.282 |
| PLT admission (K/mL) | 213 (129, 272) | 187 (142, 256) | 0.684 |
| WBC admission (K/µL) | 9.1 (7.0, 13.8) | 6.5 (5.0, 8.7) | 0.00847 |
| Lymphocytes admission (K/µL) | 71 (53, 123) | 156 (102, 214) | 0.00344 |
| CRP admission (mg/L) | 132 (88, 255) | 70 (40, 130) | 0.00399 |
| Ferritin admission (ng/mL) | 657 (319, 886) | 418 (225, 757) | 0.211 |
| D-dimer admission (ng/mL) | 1,452 (739, 2,882) | 563 (490, 1,040) | 0.0105 |
| INR admission | 1.1 (1.0, 1.2) | 1.1 (1.1, 1.2) | 1.00 |
| ALT admission (IU/I) | 31 (21, 52) | 27 (20, 40) | 0.255 |
| Cr admission (mg/dL) | 1.0 (0.8, 1.3) | 0.8 (0.7, 1.1) | 0.0428 |
| IL-18 (pg/mL) | 709 (430, 1,039) | 393 (252, 598) | 0.00426 |
| CD163 (ng/mL) | 716 (647, 1,021) | 453 (371, 665) | 0.000415 |
| mortality_30d | | | 0.00112 |
| 30-day mortality | 9 (33%) | 1 (2.3%) | |
| 30-day survival | 18 (67%) | 42 (98%) | |

[1] Statistics presented: median (IQR); n(%) [2]. Statistical tests performed: Wilcoxon rank-sum test; chi-square test of independence. Comparison of patients who needed invasive ventilation (classified as severe) to patients who did not (classified as mild), in relation to clinical and laboratory values presented in their admission. Lymphopenia, high CRP, D-dimer, sCD163, and IL-18 levels were statistically significant in the patients eventually needed invasive ventilation support.
sCD163 in correlation to COVID-19 was first described this February by Maria Antonella Zingaropoli et al., in a research which included 102 COVID-19 patients in admission in Italy and was found to be a potential marker to assess the progression of the disease [35]. In their study, sCD163 showed a statistical significance in COVID-19 patients compared with a control group of healthy blood donors. In addition, sCD163 levels in the blood of COVID-19 patients who developed ARDS were higher compared with a non-ARDS COVID-19 patients group [35].

In our study, we tested levels of sCD163 in a mortality group compared to a survival group, in which both groups were diagnosed with COVID-19. We found that levels of sCD163 were strongly correlated with severity and mortality in COVID-19 patients together with ferritin and IL-18. However, even though all three markers (ferritin, IL-18, and sCD163) were associated with ominous prognosis, there was no intercorrelation between sCD163 to either, IL-18 or ferritin (Fig. 4d). We suggest that each of the markers is associated to the progression of the disease, but is more prominent in a different phase along a common pathophysiology. We conclude from our study, and in view of the previous publications, that IL-18 might be associated to an earlier phase of the disease, while ferritin to a more advance phase and/or its peak, and sCD163 to its advance to late phase. We hypothesize that as part of macrophage activation in COVID-19, IL-18 and ferritin levels rise together with CD163 receptors on M2 macrophages. IL-18, together with FeH, might take a prominent part in the cytokine storm, while sCD163, presumably with FeL, in the advance to late anti-inflammatory phase of the disease. In addition, in recent years, studies have demonstrated that as part of the inflammatory process induced by FeH in MAS, FeH induced a significant increase in IL-18 and IL-12, which appear to also play a role in the inflammatory vicious cycle and might fill some gaps in understanding the intercorrelations processes [36]. Furthermore, IL-12 has shown a synergistic effect with IL-18 to stimulate secretion of interferon-γ which promotes Th1-type inflammatory responses [7].

In summary, while assessing the progression of COVID-19 in hospitalized patients, high levels of ferritin, sCD163, and IL-18 have been found to be important markers for predicting patients’ prognosis, along with CRP, lymphocytes, and D-dimer.

IL-18 and mainly sCD163 have played significant roles as prognostic markers among hospitalized patients, and in predicting the need of invasive ventilation and therefore can serve as therapeutic targets.

The precise role of sCD163 in the mechanism of the disease has not been discovered yet and might be a good candidate as a target to treat COVID-19, hyperferritinemic syndrome, and cytokine storm-associated diseases in general.

Author contribution Yuval Volfovitch: conceptualization, investigation, and writing — original draft. Avishai M Tsur: formal analysis and methodology. Michael Gurevitch: investigation and methodology. Daniela Novick: conceptualization, methodology, writing — original draft, and resources. Roy Rabinowitz: data analysis and visualization. Menachem Rubinstein: conceptualization. Mathilda Mandel: conceptualization. Anat Achiron: conceptualization. Yehuda Shoenfeld: conceptualization, writing — original draft, and supervision. Howard Amital: conceptualization, writing — original draft, project administration, funding acquisition, and supervision.

Declarations

Conflict of interests The authors declare no competing interests.

References

1. WHO Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int/.
2. Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395:1033–4.
3. Terpos E, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95:834–47.
4. Dahan, S. et al. Ferritin as a marker of severity in COVID-19 patients: a fatal correlation. Isr Med Assoc J 22 429–434 Preprint at (2020).
5. Ragag D, Salah Eldin H, Taemah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
6. Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93:250–6.
7. Fajjenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–73.
8. Canna SW, Cron RQ. Highways to hell: mechanism-based management of cytokine storm syndromes. J Allergy Clin Immunol. 2020;146:949–59.
9. Rodrigues TS, de Sá KSG, Ishimoto AY, et al. Inflammasesomes are activated in response to SARS-cov-2 infection and are associated with COVID-19 severity in patients. J Exp Med. 2020;218(3):e20201707. https://doi.org/10.1084/jem.20201707
10. Huang W, et al. The inflammatory factors associated with disease severity to predict COVID-19 progression. J Immunol. 2021;206:1597–608.
11. Perricone, C. et al. COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy. Immunol Res. 2020;68 213–224 Preprint at https://doi.org/10.1007/s12026-020-09145-5
12. Russitti P, et al. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. Ann Rheum Dis. 2020;79:1152–5.
13. Russitti, P. et al. Severe COVID-19. Another piece in the puzzle of the hyperferritinemic syndrome. An immunomodulatory perspective to alleviate the storm. Front Immunol. 2020;11:1–6.
14. Young BE, et al. Viral dynamics and immune correlates of coronavirus disease 2019 (COVID-19) severity. Clin Infect Dis. 2020;2019;1–11.
15. Fraser DD, et al. Inflammation profiling of critically ill coronavirus disease 2019 patients. Crit Care Explor. 2020;2:e0144.
16. Colafrancesco S, et al. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia. Immunol Res. 2014;60(2-3):177–83. https://doi.org/10.1007/s12026-014-8563-7.
17. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin Immunol. 2013;25:439–48.
18. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15:612–32.
19. Dolinay T, et al. Inflammatory-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012;185:1225–34.
20. Satś H, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302.
21. Drosté A, Sorg C, Högger P. Shedding of CD163, a novel regulatory mechanism for a member of the scavenger receptor cysteine-rich family. Biochem Biophys Res Commun. 1999;256:110–3.
22. Ettendorf A, Maniecki MB, Möller K, Möller HJ, Moestrup SK. Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol. 2010;88:1201–5.
23. Weissgerber TL, Milic NM, Winham SJ, Garovic VD. Beyond bar and line graphs: time for a new data presentation paradigm. PLoS Biol. 2015;13:1–10.
24. Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D’Cruz DP, Shoenfeld, Y. The hyperferritinemic syndrome: macrophage activation syndrome, Stuś’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:2185. https://doi.org/10.1186/1741-7015-11-185.
25. Mahroum N, et al. Ferritin - from iron, through inflammation and autoimmune, to COVID-19. J Autoimmun. 2022;126:102778. https://doi.org/10.1016/j.jaut.2021.102778.
26. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol. 2017;29:401–9.
27. Rosário C, Shoenfeld Y. The hyperferritinemic syndrome. Isr Med Assoc J. 16 664–665 Preprint (at 2014).
28. Wawrocki S, Drusszcynska M, Kowalewicz-Kulbat M, Rudnicka, W. Interleukin 18 (IL-18) as a target for immune intervention. Acta Biochim Pol. 63 59–63 Preprint at https://doi.org/10.18388/abp.2015_1153 (2016).
29. Vecchié A, et al. IL-18 and infections: is there a role for targeted therapies? J Cell Physiol. 2021;236:1638–57.
30. Canedo-Marroquin G, et al. SARS-CoV-2: immune response elicited by infection and development of vaccines and treatments. Front Immunol. 2020;11:1–19.
31. Gabay C, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis. 2018;77:840–7.
32. Canova SW, et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol. 2017;139:1698–701.
33. Sakumura N, et al. Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis. Cytokine. 2018;110:459–65.
34. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020;19(6):102538. https://doi.org/10.1016/j.autrev.2020.102538.
35. Zingaropoli MA, et al. Increased sCD163 and sCD14 plasmatic levels and depletion of peripheral blood pro-inflammatory monocytes, myeloid and plasmacytoid dendritic cells in patients with severe COVID-19 pneumonia. Front Immunol. 2021;12:1–12.
36. Ruscitti P, et al. Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Sci Rep. 2020;10(1):12232. https://doi.org/10.1038/s41598-020-69031-w.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under applicable law.

Springer Nature or its licensor holds exclusive rights to this article under applicable law.

Authors and Affiliations

Yuval Volfovitch1,2, Avishai M. Tsur1,3,4, Michael Gurevitch1, Daniela Novick5, Roy Rabinowitz6, Mathilda Mandel1, Anat Achirom1, Menachem Rubinstein5, Yehuda Shoenfeld1,7,8,9, Howard Amital1

1 Department of Medicine ‘B’, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
3 The Israel Defense Forces Medical Corps, Ramat Gan, Israel
4 Department of Military Medicine, Hebrew University of Jerusalem Faculty of Medicine, Jerusalem, Israel
5 Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
6 Department of Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
7 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
8 Ariel University, Ariel, Israel
9 Zabladowicz Center for Autoimmune Diseases, H. Sheba Medical Center, Tel Hashomer, Israel